Cough, Cold, Flu and Allergy Remedies - US - April 2018
Total sales for the cough, cold, flu, and allergy remedy market reached $9.5 billion in 2017, a 6.2% increase from 2016. The start to a record-breaking flu season has already driven an 8.7% increase in the cold and sinus remedies segment, fueled by sales of flagship, multi-functional brands such as Mucinex, Vicks, and Tylenol. The majority of consumers have experienced an ailment within the past 12 months, and seek easy-to-use, accessible, and effective remedies – mainly OTC medications – to treat symptoms. Private label and natural remedies are showing heightened growth, while consumers are prioritizing value and convenience when shopping for ailment remedies.
This report looks at the following areas:
Emphasis on value can limit market growth, constrain profit margins
Some ailment sufferers are not engaged in prompt treatment